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To determine the clinical significance of the occurrence
of hemodynamic deterioration after the administration
of calcium channel blocking drugs, nifedipine (20 mg
orally) was administered to 29 patients with severe left
ventricular dysfunction. Thirteen patients showed hemo-
dynamic improvement with the drug (Group 1), as shown
by a notable increase in cardiac index associated with a
modest decrease in mean arterial pressure. The other
16 patients exhibited hemodynamic deterioration after
nifedipine (Group 2), as reflected by a decline in right
and left ventricular stroke work indexes accompanied
by a marked hypotensive response. These differences
were not related to differences in the peripheral vascular
response to nifedipine, because both groups showed sim-
ilar decreases in systemic and pulmonary vascular re-
sistances.
Groups 1 (hemodynamic improvement) and 2 (hemo-
dynamic deterioration) were similar with respect to all
demographic variables and pretreatment left ventricular
performance (cardiac index, left ventricular filling pres-
sure and systemic vascular resistance). Yet, the 1 year
actuarial survival in patients in Group 1 was substan-
Patients with severe chronic heart failure have a highly
unfavorable long-term prognosis; 30 to 50% of patients with
advanced left ventricular dysfunction who remain sympto-
matic on digitalis and diuretic therapy die within I year,
and 60 to 80% die within 2 years (1-7). A variety of clinical.
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tially better than that in patients in Group 2 (67 versus
23%, p =0.009). Group 2, however, had higher values
for plasma renin activity (17.7 ± 6.0 versus 4.3 ± 1.4
mg/ml per h, p < 0.05), lower values for serum sodium
concentration (134.6 ± 1.2 versus 139.2 ± 0.6 mEq/liter,
p < 0.05) and higher values for mean right atrial pres-
sure (15.8 ± 2.0 versus 7.9 ± 1.4 mm Hg, p < 0.01)
than did patients in Group 1. Previous work has iden-
tified these three variables as important determinants of
survival in patients with severe chronic heart failure;
yet, the hemodynamic response to nifedipine was more
powerful than any of these three variables in predicting
long-term prognosis.
These findings confirm the hypothesis that patients
with the most advanced heart failure (as reflected by
their poor long-term survival) are most likely to show
hemodynamic deterioration after calcium channel block-
ade, and they suggest that the assessment of neurohor-
monal activation and right ventricular performance more
accurately identifies such patients than do conventional
measures of left ventricular performance.
(J Am Coli CardioI1987;10:1303-11)
hemodynamic and hormonal variables have been identified
that correlate with mortality in these patients, but the relative
importance of these variables has varied according to the
population under study. In studies (l,2) that evaluated pa-
tients with a wide range of symptoms, hemodynamic vari-
ables (such as cardiac index, left ventricular filling pressure
and left ventricular stroke work index) were powerful prog-
nostic variables. In contrast, in studies (4,6,7) that confined
their evaluation to very ill patients, neurohormonal acti-
vation and right ventricular function were the principal pre-
dictors of long-term survival. Unfortunately, all of the vari-
ables evaluated in these previous studies were indirect
reflections of the severity of the underlying degree of myo-
cardial impairment, because direct measurements of myo-
cardial contractile force are nearly impossible to perform in
the clinical setting; conventional hemodynamic variables are
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highly load dependent (8), and sophisticated calculations of
stress-shortening relations are difficult to interpret in patients
with asymmetric left ventricular dysfunction and dilation
(9).
Conceptually, an excellent approach to assessing the in-
tegrity of the intrinsic myocardial contractile apparatus is
to measure the response of patients with left ventricular
dysfunction to the administration of a negative inotropic
agent. Insofar as patients with the greatest degree of myo-
cardial impairment would be expected to show the most
marked hemodynamic deterioration after pharmacologic
cardiodepression, the administration of such an agent (for
example, a calcium-entry blocker) could provide important
prognostic information. Because calcium is essential for
activation of contractile proteins, calcium channel blocking
drugs exert potent direct negative inotropic effects in iso-
lated cardiac muscle preparations (1O,II) . In patients with
normal cardiovascular function, this cardiodepressant action
is offset by the systemic vasodilator effects of these drugs;
the resultant activation of the sympathetic nervous system
and the reduction of ventricular afterload act to maintain
ventricular performance (12-15). In patients with compro-
mised left ventricular function , however, there is an im-
paired ability to deliver calcium ions to myofibrillar ele-
ments (16,17); hence, the myocardium is exquisitely sensitive
to agents that further reduce the availability of intracellular
calcium (18). In addition, the sympathetic nervous system
is already greatly activated in these patients, and adrenergic
reflex mechanisms that are crucial to the support of circu-
latory homeostasis during calcium channei blockade are
markedly attenuated (19,20). Consequently, these patients
may experience notable hemodynamic and clinical deteri-
oration after the administration of calcium channel blocking
drugs (21-27). Can such a pharmacologic response be used
to predict long-term survival in these patients? The present
analysis was designed to address this question.
Methods
Study patients. The study group consisted of 29 patients
with chronic congestive heart failure, who received a trial
of nifedipine for therapeutic purposes, on the basis of reports
of hemodynamic and clinical improvement after short- and
long-term therapy with the drug (28-31) . All patients had
a left ventricular ejection fraction < 35% as determined by
radionuclide ventriculography . There were 19 men and 10
women , aged 27 to 80 years (mean 61) . The cause of heart
failure was coronary artery disease in IS patients, primary
dilated cardiomyopathy in 13 and persistent severe left ven-
tricular dysfunction after mitral valve replacement in one
patient. All patients were evaluated while clinically stable.
Hemodynamic determinations. Before entry into the
study, all patients were hospitalized for a minimum of 5
days, during which time doses of digitalis and diuretics
remained constant and all vasodilator drugs were discontin-
ued. After written, informed consent was obtained , right
heart catheterization and arterial cannulation were per-
formed for measurement of intracardiac and systemic pres-
sures, respectively; patients were then permitted to rest over-
night to permit dissipation of hemodynamic changes related
to intravascular instrumentation (32). Left ventricular filling
pressure was estimated by the mean pulmonary capillary
wedge pressure. Thermodilution cardiac output was deter-
mined in triplicate by a bedside cardiac output computer
using iced injectate. Patients were kept at bed rest and in a
postprandial state during all hemodynamic measurements to
avoid circulatory changes that accompany eating or changes
in position.
Drug administration. The following hemodynamic
variables were measured repeatedly for at least 2 hours (with
a variation of < 10%) to ensure stability of the pretreatment
state before drug administration: mean arterial pressure, heart
rate, left ventricular filling pressure, mean right atrial pres-
sure and cardiac output. Each patient then received a single
dose of 20 mg of nifedipine orally . This dose was chosen
because of its established utility in the treatment of ischemic
heart disease and because similar doses of the drug have
been evaluated in previous studies of patients with left ven-
tricular dysfunction (22,30,31 ,33-37) . After drug admin-
istration, all hemodynamic variables were reassessed every
15 minutes for I hour and then every 30 minutes for an
additional 2 hours.
Biochemical determinations. Blood samples were col-
lected before the administration of nifedipine for determi-
nation of serum sodium concentration, blood urea nitrogen
and serum creatinine concentration in all patients and for
measurement of plasma renin activity in 22 of the 29 pa-
tients. All samples were drawn at a similar time of the day ,
while patients Were consuming a 2 g sodium diet, and after
at least 4 hours in the supine position .
Long-term clinical follow-up. After completion of the
invasive hemodynamic studies, all patients were treated with
isosorbide dinitrate, hydralazine or captopril, alone or in
combination, in addition to digitalis and diuretics; no patient
received long-term treatment with any calcium channel
blocking drug . in 25 of the 29 patients, long-term survival
was assessed from the day of nifedipine administration to
the day of death or , if alive, to the date of the present
analysis; all patients were followed up for at least I year.
Long-term follow-up data were not available in four pa-
tients .
Data analysis. Mean systemic and pulmonary artery
pressures were determined by electronic filtration. Derived
hemodynamic variables were calculated as follows:
Cardiac index (CI) = CO/body surface area (liters/min per
rrr'),
Stroke volume index (SVI) = Cllheart rate (ml/m"),
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LY stroke work index (LYSWI) =
(MAP - LYFP) x SVI x 0.0136 (g-rn/m''),
RY stroke work index (RVSWl) =
(M PAP - MRAP) x SVI x 0.0136 (g-rn/rrr'),
Systemic vascular resistance =
80 x (MAP - MRAP)/CO (dynes-s-cm t " ) ,
Pulmonary vascular resistance =
80 x (MPAP - LVFP)/CO (dynes-s-cm 5),
whereCO = cardiac output, MAP = mean systemic arterial
pressure, LV = left ventricular. RV = right ventricular,
LVFP = left ventricular filling pressure, MPAP = mean
pulmonary artery pressure and MRAP = mean right atrial
pressure.
The hemodynamic effects of nifedipine were assessed at
the peak effect of the drug on systemic vascular resistance.
30 to 60 minutes after its administration. Patients were then
classified into two groups based on whether the change in
left ventricular stroke work index after the administration
of nifedipine was greater than or less than the mean decline
of 25%; this variable was used because it reflects global left
ventricular performance better than do the other hemody-
namic variables we measured and has been used to distin-
guish among subgroups treated with vasodilator drugs in
previous studies (38,39). In 16patients, nifedipine produced
a ::::25% decline in left ventricular stroke work index; these
patients were considered to have had hemodynamic dete-
rioration during the study (Group 2). In the remaining 13
patients, nifedipine produced little change (::;15%) or an
increase in left ventricular stroke work index; these patients
showed marked increases in cardiac output and were con-
sidered to have had hemodynamic improvement (Group I) .
Quantitative and qualitative differences between the two
groups were evaluated by the t test for independent variables
and by Fisher's exact test, respectively. The hemodynamic
effects of nifedipine within each group were compared with
their respective control values by the t test for paired data
and with each other by analysis of variance. Cumulative
survival curves were constructed using the Kaplan-Meier
survivorship method (40), and differences between survival
curves were tested for significanceby both Mantel-Cox log-
rank and Wilcoxon-Breslow methods (41,42). All group
data are expressed as mean ± SEM.
Results
In the 29 patients in our study, nifedipine produced no-
table increases in cardiac index and stroke volume index
and decreases in mean arterial pressure, left ventricular stroke
work indexand systemic and pulmonary vascular resistances
without significantchanges in left ventricularfillingpressure
or heart rate (Table I).
Differential hemodynamic effects of nifedipine in
Groups 1 and 2 (Fig. 1 to 3). In the 13 patients in the
hemodynamic improvement group (Group I) , nifedipine
Table 1. Overall Hemodynamic Response to Nifedipine in All
29 Patients With Severe Chronic Heart Failure
Control Nifedipine p Yalue*
Cardiac index 1.98 ± 0.09 2.31 ± 0.13 < 0.0 1
(liters/min per rrr' )
Stroke volume index 24.5 ± 1.5 27.8 ± 1.7 < 0.02
(rnt/m')
Left ventricular filling 24.9 ± 1.7 23.9 ± 1.4 NS
pressure (mm Hg)
Mean arterial pressure 83.2 ± 2.2 60.7 ± 2.0 < 0.00 1
(mm Hg)
Mean right atrial 12.3 ± 1.4 13.4 ± 1.5 NS
pressure (mm Hg)
Left ventricular stroke 19.5 ± 1.4 14.8 ± I.7 < 0.00 1
work index (g-rn/nr')
Right ventricular stroke 8.7 ± 0.7 7.8 ± 0.8 NS
work index (g-rn/rn' )
Heart rate 81.8 ± 2. 1 83.8 ± 3.3 NS
(beats/min)
Systemic vascular 1,851 ± 124 993 ± 70 < 0.00 1
resistance
(dynes-s-cm - 5)
Pulmonary vascular 346 ± 33 237 ± 24 < 0.001
resistance
(dynes-s-cm- 5)
*Significance of differences between pretreatment and post-treatment
values.
produced a marked increase in cardiac and stroke volume
indexes (both p < 0.001) and a marked decrease in systemic
and pulmonary vascular resistances (43 and 30%, respec-
tively). These benefits were associated with moderate de-
crease in mean systemic arterial pressure ( - 17.2 mm Hg),
but no significant change in right or left ventricular filling
pressures, right or left ventricular stroke work indexes or
Figure I. Values forcardiac index, stroke volume index and mean
arterial pressure before and after nifedipine in patients with severe
chronic heart fai lure whoshowed hemodynamic improvement (IMP)
(Group I) or hemodynamic deterioration (DTR) (Group 2) after
administration of thedrug. *p < 0.001 , significance of difference
between pre- and post-treatment values within each group; the p
values at the top of eacb panel designate the significance of dif-
ference between the two groups in the magnitude of drug-induced
changes. Group data are expressed as mean values ± SEM.
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Figure2. Values for left ventricular stroke work index, left ven-
tricular filling pressure and systemic vascular resistance before and
after theadministration of nifedipine inGroup I (IMP) and Group
2 (DTR). Format and abbreviations as in Figure I. *p < 0.001.
Figure 3. Values for right ventricular stroke work index, mean
right atrial pressure and pulmonary vascular resistance before and
after theadministration of nifedipine inGroup 1 (IMP) and Group
2 (DTR). Format and abbreviations as in Figure I. *p < 0.00I;
t p < 0.01; :f:p < 0.05.
heart rate. In contrast, despite decreases in systemic and
pulmonary vascular resistances similar to those seen in Group
I (49 and 32%, respectively) , the 16 patients in the hemo-
dynamicdeterioration group (Group 2) showed a significant
declinein rightand left ventricularstroke workindexes(both
p < 0.001 ) without an improvement in cardiac or stroke
volume indexes. This unfavorable response was accompa-
niedby a markeddecreasein mean systemicarterialpressure
( - 27.0 mm Hg, p < 0.00 I), no change in left ventricular
filling pressure and a significant increasein mean right atrial
pressure ( + 3.3 mm Hg, p < 0.01). Of the hemodynamic
variables measured in this study, the effects of nifedipine
on cardiac and stroke volume indexes (p < 0.001) , right
and left ventricularstroke work indexes (p < 0.001), mean
right atrial pressure (p < 0.05) and mean arterial pressure
(p < 0.02) were significantly different between the two
groups.
Pretreatment clinical and hemodynamic character-
istics of Groups 1 and 2 (Table 2). Groups I and 2 were
similar with respect to age, sex, etiology of heart failure,
renal function, left ventricular ejection fraction and pre-
treatmentvalues for cardiac and stroke volume indexes. left
ventricular filling pressure, mean arterial pressure, right and
left ventricular stroke work indexes, heart rate and systemic
and pulmonary vascular resistances. Patients in Group 2,
however, had significantly higher pretreatment values for
mean right atrial pressure than did patients in Group I (15.8
± 2.0 versus7.9 ± 1.4 mm Hg, p < 0.01). The proportion
of patients with a mean right atrial pressure ;:::: 12 mm Hg
was significantly greater in Group 2 (I I of 16 patients) than
in Group I (2 of 13 patients), (p < 0.02). In addition,
patients in Group2 had higher pretreatment values for plasma
renin activity (17.7 ± 6.0 versus 4.3 ± lA, P < 0.01)
and lower pretreatment values for serum sodium concen-
tration (134.6 ± 1.1 versus 139.2 ± 0.6 , P < 0.01) than
did patients in Group I. The proportion of patients with a
serum sodium concentration :::; I37 mEq/liter was signifi-
cantly greater in Group 2 (12 of 16 patients) than in Group
I (2 of 13 patients) (p < 0.02).
Differential clinical effects of nifedipine in Groups 1
and 2. Eight (28%) of the 29 patients in this study expe-
rienced dyspnea or dizziness, or both, within 60 minutes
after the administration of nifedipine. In three patients, these
adverse reactions were mild and disappeared without spe-
cific therapyas the hemodynamic effects of the drug waned
over time. Five patients, however, developed a clinical pic-
ture of cardiogenic shock (severe dyspnea and profound
symptomatic hypotension) that was not responsive to intra-
venous calcium chloride and required intravenous levarter-
enol for blood pressure support for 4 to 10 hours after the
administration of nifedipine. All patients recovered un-
eventfully, and repeat hemodynamic evaluation performed
24 hours later showeda return of all hemodynamic variables
to pre-nifedipine values. Values for serum sodium concen-
trationand plasmarenin activity in these five patients varied
from 126 to 135 mEq/liter and from 3.1 to 64.0 ng/ml per
h, respectively . Of the seven patients in our study with a
pretreatment plasma renin activity > 10 ng/ml per h, three
experienced cardiovascular collapse after administration of
the drug and required intravenous pressors for blood pres-
sure support. In contrast, only one of nine patients with a
plasma renin activity < 3 ng/ml per h experienced any ad-
verse clinicaleffects, and this reactionconsisted of transient
dyspnea that did not require specific therapy.
Long-term follow-up. After completion of the nifedi-
pine study, all patients were treated with isosorbide dini-
trate, hydralazine or captopril, alone or in combination, and
followed up for at least I year. The treatment regimens used
and the durationof follow-upwere similar in the two groups
(762 ± 114 days in Group I and 643 ± 80 days in Group
.
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Table 2. Pretreatment Clinical, Biochemical and Hemodynamic Variables in Patients in Groups
I and 2
Group I
(n = 13)
Group 2
(n = 16) p Yalue*
Age
Sex
Cause of CHF
LY ejection fraction
Serum sodium (mEg/liter)
BUN (rng/dl)
Serum Cr (mg/dl)
PRA (ng/ml per h)
CI (liters/min per rrr')
SYI (rnl/m'')
HR (beats/min)
LYFP (mm Hg)
MAP (mm Hg)
MRAP (mm Hg)
LYSWI (g-rn/rrr')
RYSWI (g-m/rrr')
SYR (dynes-s-cm 5)
PYR (dynes-s-cm - 5)
66.1 ± 3.4
8M.5F
[CM 8. POC 5
0.20 ± 0.02
139.2 ± 0.6
39.6 ± 7.0
1.5 ± 0.1
4.3 ± 1.4
I. 95 ± .11
25.4 ± 1.7
77.8 ± 2.9
23.2 ± 1.9
83.7 ± 3.7
7.9 ± 1.4
20.8 ± 1.7
9.2 ± 0.8
1,824 ± 143
278 ± 36
56.8 ± 4.0
IIM,5F
[CM 7. POC 8. MYR I
0.17 ± .01
134.6 ± 1.1
50.9 ± 6.4
1.6 ± 0.2
17.7 ± 6.0
2.01 ± .15
23.7 ± 2.4
85.0 ± 2.8
26.3 ± 2.6
82.9 ± 2.6
158 ± 2.0
18.5 ± 2.2
8.2 ± 1.1
1.874 ± 197
401 ± 50
NS
NS
NS
NS
<0.01
NS
NS
<0.01
NS
NS
NS
NS
NS
<0.0\
NS
NS
NS
NS
*Significance of differences between the two groups. BUN blood urea nitrogen; CHF = congestive
heart failure; C[ = cardiac index; Cr = creatinine; F = female; HR = heart rate; [CM = ischemic heart
disease; LY = left ventricular; LYFP = left ventricular filling pressure; LYSW[ = left ventricular stroke
work index; M = male; MAP = mean arterial pressure; MRAP = mean right atrial pressure; MYR = mitral
valve replacement for valvular heart disease; POC = primary dilated cardiomyopathy; PRA = plasma renin
activity; PYR = pulmonary vascular resistance; RYSW[ = right ventricular stroke work index; SYI = stroke
volume index; SYR = systemic vascular resistance.
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Figure 4. Kaplan-Meier analysis showing cumulative rates of sur-
vival inpatients who hadsevere chronic heart failure stratified into
two groups onthebasis of theirimmediate hemodynamic response
to a single dose of nifedipine (Groups I [IMP] and 2 [DTR]) but
who received long-term treatment with conventional vasodilator
drugs (nitrates, hydralazine andcaptopril). Patients who hadhemo-
dynamic improvement after nifedipine (Group I) fared signifi-
cantly better than didpatients who had hemodynamic deterioration
(Group 2) (p = 0.009, Wilcoxon-Breslow and Mantel-Cox).
100
Discussion
The findings of the present study confirm previous ob-
servations that nifedipine may cause hemodynamic im-
provement or deterioration in patients with congestive heart
failure (22). Nearly half of our patients (Group 1) showed
2). In Group I, patients were treated with a converting
enzyme inhibitor alone (four patients), a direct-acting vaso-
dilator alone (four patients) and both classes of drugs in
combination (five patients). In Group 2, patients were treated
with a converting enzyme inhibitor alone (six patients), a
direct-acting vasodilator alone (six patients) and both classes
of drugs in combination (four patients).
During the course of follow-up, patients in Group I fared
significantly better than did patients in Group 2 (median
survival 486 versus 108 days, respectively; p = 0.009 by
Mantel-Cox and Wilcoxon-Breslow) (Fig. 4); the I year
actuarial survival was 67% in Group I compared with 23%
in Group 2. At the time of most recent follow-up, the pro-
portion of patients who were alive was significantly greater
in Group I (8 of 12 patients) than in Group 2 (2 of 13
patients) (67 versus 15%, p < 0.05).
All pretreatment clinical, hemodynamic and biochemical
variables shown in Table 2 (except for plasma renin activity)
were entered together with the observed hemodynamic re-
sponse to nifedipine into a Cox proportional hazards model
with the use of stepwise regression analysis; because plasma
renin activity was measured in only 22 patients, it was not
entered into this analysis. Of all variables that were signif-
icantly different between Groups I and 2, the change in left
ventricular stroke work index after nifedipine was the most
powerful predictor of long-term survival.
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notable hemodynamic improvement after nifedipine, as
manifested by a marked increase in cardiac index that was
accompanied by only a modest decline in mean arterial
pressure. In contrast, the other half of our patient cohort
(Group 2) experienced notable hemodynamic deterioration
after nifedipine, as reflected by a decline in right and left
ventricular stroke work indexes that was accompanied by a
marked hypotensive response. These differences could not
be explained by differences in the peripheral vascular re-
sponse to nifedipine (22), because both groups showed sim-
ilar decreases in systemic and pulmonary vascular resis-
tance. They also could not be ascribed to changes in loading
conditions, because (in addition to similar changes in sys-
temic vascular resistance) right and left ventricular filling
pressures failed to change significantly in either group. Hence,
we must attribute the different hemodynamic responses we
observed in the two groups to a significant depression of
myocardial contractility induced by nifedipine in Group 2.
Nifedipine response as a measure of disease severity.
Why should patients in the hemodynamic deterioration group
have been so exquisitely sensitive to the cardiodepressant
effects of nifedipine? The delivery of calcium to the con-
tractile proteins is thought to be profoundly compromised
in states of severe myocardial dysfunction (16,17) and, thus,
any drug that impedes the movement of calcium into the
cell can critically impair contractile performance (43). Con-
sequently, we should be able to assess the integrity of the
intrinsic myocardial contractile apparatus by measuring the
response of patients with left ventricular dysfunction to the
administration of a negative inotropic agent. Recent expe-
rience with beta-adrenergic blocking drugs suggests the va-
lidity of this approach. Patients with heart failure who have
the highest circulating levels of norepinephrine (44) and the
most severe histologic changes on myocardial biopsy (45)
are most susceptible to hemodynamic deterioration after
short-term beta-receptor blockade; such hormonal or his-
tologic markers also identify patients with heart failure who
have the most unfavorable long-term prognosis (6,46). No
previous study, however, has shown a direct relation be-
tween the short-term hemodynamic response to a cardiode-
pressant drug and long-term survival. Our observation that
the response to nifedipine was the most powerful predictor
of long-term prognosis 1) strongly supports the concept that
patients with the most advanced heart failure (as determined
by their high mortality) have the greatest susceptibility to
the administration of a negative inotropic agent; and 2)
suggests that the availability of calcium to myofibrillar ele-
ments declines in parallel with the severity of the heart
failure state.
Hemodynamic variables as a measure of disease se-
verity. Because the response to nifedipine may be delete-
rious in patients with severe congestive heart failure, we
would like to be able to measure the severity of the under-
lying disease process without the use of a "nifedipine chal-
lenge. " Can conventional measures of left ventricular func-
tion identify the most severely ill individuals? In our study,
as well as in previous reports (22), pretreatment values for
cardiac output, left ventricular stroke work index, left ven-
tricular filling pressure, systemic vascular resistance and left
ventricular ejection fraction did not differ between the hemo-
dynamic improvement and deterioration groups, and, thus,
did not determine the susceptibility to adverse reactions after
calcium channel blockade. Why do such conventional mea-
sures of cardiac performance fail to accurately assess the
severity of myocardial impairment in patients with severe
congestive heart failure? Conventional measures of ventric-
ular function are load dependent (8,9) and, thus, do not
accurately assess contractile function or the severity of the
intrinsic disease process. Furthermore, clinically important
changes in ventricular performance may be very difficult to
discern in a patient whose myocardial function is already
severely compromised. These concepts may explain why
conventional hemodynamic variables (when severely ab-
normal) do not provide independent prognostic information
in patients with severe heart failure (6,7), and why left
ventricular function may show little deterioration during the
long-term follow-up of these patients, even though the un-
derlying disease presumably continues to progress and ul-
timately leads to the death of the patient (47).
Prognostic variables as a measure of disease severity.
How then can we measure the severity of the underlying
disease process and thereby identify those patients with heart
failure whose contractile function is most dependent on
available stores of intracellular calcium? Insofar as the se-
verity of the disease process is the principal determinant of
the survival of the myocardial cell, it would appear that
variables that predict long-term survival would provide the
most accurate estimate of disease severity and would there-
fore predict the susceptibility to calcium channel blockade.
Accordingly, patients who experienced hemodynamic and
clinical deterioration after treatment with nifedipine showed
higher pretreatment values for plasma renin activity and
mean right atrial pressure and lower pretreatment values for
serum sodium concentration than did patients who tolerated
the drug without difficulty; all three variables have been
shown to be powerful predictors of long-term survival of
patients with severe congestive heart failure (4,6,7,48). This
observation may explain the findings of previous reports,
in which nifedipine produced short-term hemodynamic im-
provement in most patients with heart failure (who generally
have a normal serum sodium concentration and preserved
right ventricular function) (49), but caused detrimental cir-
culatory effects in patients who had markedly increased
values for plasma renin activity or mean right atrial pressure
before therapy (23,26). Yet, of all the predictive variables
that we evaluated in the present study, the immediate hemo-
dynamic response to nifedipine provided the most powerful
prognostic information.
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Alternative explanations for our observations should be
considered, The elevated values for mean right atrial pres-
sure in patients in the hemodynamic improvement group
might reflect a marked expansion of intravascular volume,
presumably the result of the notable activation of the renin-
angiotensin system that we measured in these individuals.
Such sodium retention could conceivably attenuate the re-
sponsiveness of peripheral vessels to vasodilator stimuli (50),
and if the vasodilating effects of nifedipine were attenuated,
the cardiodepressant effects of this drug might become more
apparent (43), Although attractive, this sequence of events
appears unlikely, however, because patients in the hemo-
dynamic improvement and deterioration showed similar de-
creases in systemic vascular resistance. On the other hand,
the adverse reactions that we noted in the hemodynamic
deterioration group might have been the result of excessive
vasodilation, resulting in a marked hypotensive response
that may have compromised perfusion of the right and left
ventricles. If true, the deterioration of right and left ven-
tricular performance that we noted after nifedipine would
not be the consequence of a direct negative inotropic action
but would result from right and left ventricular ischemia,
especially in patients who had severe obstructive coronary
artery disease and who would have been highly susceptible
to changes in coronary perfusion pressure. We do not be-
lieve, however, that the hypotensive effects of nifedipine
in our patients were of primary pathophysiologic impor-
tance, because five hyponatremic patients in the hemody-
namic deterioration group were subsequently treated with
captopril and showed notable increases in cardiac output
despite marked hypotensi ve responses (51) that were similar
in magnitude to those seen after nifedipine. Therefore, the
marked hypotensive response was likely the result (and not
the cause) of the drug's cardiodepressant actions.
Limitations of the present study. Our study was de-
signed only to evaluate the immediate hemodynamic tol-
erability of calcium channel blockade in patients with severe
heart failure, and it did not attempt to assess the long-term
utility or safety of this therapeutic approach in favorably
altering loading conditions in the failing left ventricle. Al-
though single doses of nifedipine produced short-term
hemodynamic improvement in some patients (our hemo-
dynamic improvement group), we do not wish to suggest
that these favorable effects are necessarily sustained during
long-term treatment or are accompanied by clinical benefits.
There is little relation between the first-dose response to a
vasodilator drug and the drug's long-term efficacy, whether
patients are treated with conventional agents (52-54) or the
calcium channel blocking drugs (37). Furthermore, doses
of nifedipine that are well tolerated initially may produce
cumulative deleterious effects during prolonged treatment.
Our short-term data are important, however, in that they
enable us to identify patients with severe heart failure who
are so ill that they show immediate hemodynamic deterio-
ration after an intervention that impedes the delivery of
calcium ions to myofibrillar contractile elements. This risk
is sufficiently great that we would advise strongly against
the use of a "nifedipine challenge" (in clinical practice) to
assess the severity of the underlying disease in patients with
heart failure.
Conclusions. In conclusion, conventional measures of
left ventricular function are an insensitive means of iden-
tifying patients with heart failure whose contractility is so
severely impaired that cardiac performance deteriorates after
calcium-entry blockade, despite drug-induced vasodilation.
Although the measurement of conventional hemodynamic
variables is valuable in the management of acute heart fail-
ure, clinically important changes in cardiac performance
may be extremely difficult to discern in the patient whose
myocardial function is severely and chronically impaired
(55). Under such circumstances, the only sign of disease
progression may be the onset of compromised end-organ
perfusion, as reflected by the activation of endogenous neu-
rohormones and the development of the hyponatremic state
(7,56). Alternatively, patients with such severe impairment
of myocardial contractility may be identified by determining
their susceptibility to the administration of a cardiodepres-
sant agent. Previous studies (6,7) have shown the prognostic
importance of neurohormonal activation; the present study
documents the prognostic significance of drug-induced car-
diodepression. Therefore, in patients with severe chronic
heart failure, central hemodynamic measurements at rest
may provide little prognostic information unless the myo-
cardium is pharmacologically stressed and should be con-
sidered less important than the adequacy of peripheral end-
organ perfusion in assessing the severity of the underlying
disease.
We are indebted to the nurses, cardiology fellows and staff of the Ames
and Rose Cardiac Care Units for the excellent care they provided for the
patients in this study.
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